“So, I think we're going to see a return to growth and into next year we really feel the full force of those launches.”

In context

“ff. So Larry, in the US what we had experienced was the first time ever a competitor in the cryo segment, so we had a 100% market share and we had the competitor ramp up their production, we felt that in the fourth quarter. I think there's also some anticipation for some new products we're launching including Nitron Console a refresh on our capital equipment for cryo. And of course the PulseSelect, which just started its launch in United States after the quarter closed. And that's doing very, very well, the feedback has been exceptional, doing well in the United States, doing well outside the United States. And I think those catalysts to growth of Pulsed Field for both the PulseSelect, that's the single-shot technology as well as our point-by-point ablation is driving a lot of enthusiasm. So, I think we're going to see a return to growth and into next year we really feel the full force of those launches. So it's a step-back certainly in the United States with the 11% growth worldwide or outside the United States, I should say, is giving us a lot of confidence. This is a pipeline that's poised to return us to growth in that segment. Karen Parkhill: Thanks, Sean. And on FY'25 Larry, I would just start with the fact that we're really pleased with our performance through these last several quarters. Q3 was another solid quarter, our fifth consecutive quarter of solid mid-single-digits. And I would point out that we drove that mid-single-digit growth this quarter off of mid-single-digit comps last year. And that's what we expect to continue into FY'25, you know, we've been working through our planning process, and we expect to wrap that up in advance of our Q4 earnings call. So we'll give our”